Clinical Trial Update: To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL [Phase 2]

View source ↗

Summary

Phase 2 trial comparing BI 836826-GemOx vs R-GemOx in relapsed/refractory diffuse large B-cell lymphoma to determine dose and efficacy; study completed with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• BI 836826-GemOx
• R-GemOx (rituximab, gemcitabine, oxaliplatin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Lymphoma, Large B-Cell, Diffuse | Phase 2 | Status: COMPLETED | Results posted: 2019-06-17